In the first quarter, total U.S. sales of Eylea and Eylea HD dropped by 26% year over year to $1.04 billion, but revenue from the latter increased by 54% year over year to $307 million. Eylea HD ...

Even though a setback in a clinical trial and declining Eylea sales may logically lead to a compression in valuation multiples, we believe the selling pressure on REGN stock at values below $500 ...

2. Regeneron Pharmaceuticals. Regeneron is facing biosimilar competition for Eylea, one of its biggest growth drivers. In the first quarter, the company's revenue decreased by 4% year over year to ...

U.S. sales of Eylea HD increased by 54% year over year to $307 million in the period. This version of Eylea should continue to steal some patients away from the old formulation due to the former's ...

Potential Positives. Strategic in-licensing agreement with Hansoh Pharmaceuticals provides exclusive rights to develop and commercialize HS-20094, enhancing Regeneron's pipeline in obesity and ...

Regeneron is facing biosimilar competition for Eylea, one of its biggest growth drivers. In the first quarter, the company's revenue decreased by 4% year over year to $3 billion.

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass ...

On May 20, Regeneron Pharmaceuticals — a U.S.-based biotechnology company best known for drugs like Dupixent and Eylea — was approved as the lead bidder to acquire substantially all of 23andMe ...

In a comprehensive study of geographic atrophy (GA) treatment, Deepak Sambhara, MD, from the Eye Clinic of Wisconsin analyzed long-term patient compliance with two recently FDA-approved complement ...

At Regeneron, we are developing a pipeline focused on the quality of weight reduction. We have several independent approaches focused on promoting and preserving muscle during weight loss, so as to ...

The seasoned patent litigators join from Mayer Brown, bringing decades of high-stakes experience in pharma and biotech patent disputes, including work on Hatch-Waxman and biosimilar litigation.

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of ...